Tumor Biology

, Volume 34, Issue 6, pp 3423–3430

Prognostic value of cyclin E expression in breast cancer: a meta-analysis

Research Article

DOI: 10.1007/s13277-013-0915-8

Cite this article as:
Gao, S., Ma, JJ. & Lu, C. Tumor Biol. (2013) 34: 3423. doi:10.1007/s13277-013-0915-8

Abstract

Cyclin E is an important regulator of cell cycle progression. Various studies examined the relationship between cyclin E overexpression with the clinical outcome in patients with breast cancer but yielded conflicting results. Electronic databases updated to May 2013 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between cyclin E overexpression and survival of patients with breast cancer. Survival data were aggregated and quantitatively analyzed. We conducted a final analysis of 7,759 patients from 23 eligible studies and evaluated the correlation between cyclin E overexpression and survival in patients with breast cancer. Combined hazard ratios suggested that cyclin E overexpression had an unfavorable impact on overall survival (OS) (hazard ratio (HR) = 1.30, 95 % confidence interval (CI), 1.12–1.49) and breast cancer-specific survival (BCSS) (HR = 1.48, 95 % CI, 1.03–1.93), but not disease-free survival (HR = 1.11; 95 % CI, 0.96–1.27) in patients with breast cancer. Significantly, risks were found among stage I–II breast cancer for (HR = 1.75; 95 % CI, 1.30–2.19). Cyclin E overexpression is associated with poor OS and BCSS in breast cancer.

Keywords

Cyclin EBreast cancerPrognosisDisease-free survivalMeta-analysis

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  1. 1.State Key Laboratory of Reproductive Medicine, Department of Breast SurgeryNanjing Maternity and Child Health Care Hospital Affiliated to Nanjing Medical UniversityNanjingChina